Journal ArticleDOI
Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): Results of the ASCEND-1 trial.
Dong Wan Kim,Ranee Mehra,Daniel Shao-Weng Tan,Enriqueta Felip,Laura Q.M. Chow,D. Ross Camidge,Johan Vansteenkiste,Sunil Sharma,Tommaso De Pas,Gregory J. Riely,Benjamin Solomon,Juergen Wolf,Michael Thomas,Martin Schuler,Geoffrey Liu,Armando Santoro,Margarida Geraldes,Anthony Boral,A. Yovine,Alice T. Shaw +19 more
Reads0
Chats0
TLDR
Ceritinib (LDK378) is a novel ALK inhibitor (ALKi) more potent than CRZ in enzymatic and cell-busting activities, and may be a viable alternative to crizotinib in patients with NSCLC.Abstract:
8003^ Background: ALK+ NSCLC is sensitive to crizotinib (CRZ) but patients (pts) invariably progress. Ceritinib (LDK378) is a novel ALK inhibitor (ALKi) more potent than CRZ in enzymatic and cell-b...read more
Citations
More filters
Journal ArticleDOI
Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
TL;DR: This guideline update reflects changes in evidence since the previous guideline and recommends combination cytotoxic chemotherapy is recommended, guided by histology, with early concurrent palliative care.
Journal ArticleDOI
Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2
Lucio Crinò,Myung-Ju Ahn,Filippo de Marinis,Harry J.M. Groen,Heather A. Wakelee,Toyoaki Hida,Tony Mok,David R. Spigel,Enriqueta Felip,Makoto Nishio,Giorgio V. Scagliotti,Fabrice Branle,Chetachi Emeremni,Massimiliano Quadrigli,Jie Zhang,Alice T. Shaw +15 more
TL;DR: Consistent with its activity in ASCEND-1, ceritinib treatment provided clinically meaningful and durable responses with manageable tolerability in chemotherapy- and crizotinib-pretreated patients, including those with brain metastases.
Journal ArticleDOI
Alectinib Salvages CNS Relapses in ALK-Positive Lung Cancer Patients Previously Treated with Crizotinib and Ceritinib
Justin F. Gainor,Carol A. Sherman,Kathryn Willoughby,Jennifer A. Logan,Elizabeth Kennedy,Priscilla K. Brastianos,Andrew S. Chi,Alice T. Shaw +7 more
TL;DR: Alectinib is active in ALK-rearranged NSCLC patients with LM, including in patients previously treated with crizotinib and ceritinib, and three of four patients experienced significant clinical and radiographic improvements in LM upon treatment with alect inib.
Journal ArticleDOI
Targeting brain metastases in ALK-rearranged non-small-cell lung cancer
TL;DR: Potential pathways to target ALK-rearranged brain metastases are discussed, including next generation ALK inhibitors with greater CNS penetration and mechanisms to overcome resistance.
Journal ArticleDOI
ALK: a tyrosine kinase target for cancer therapy.
Vijaykumar Holla,Yasir Elamin,Ann Marie Bailey,Amber Johnson,Beate C. Litzenburger,Yekaterina B. Khotskaya,Nora S. Sanchez,Jia Zeng,Abu Shufean,Kenna R. Shaw,John Mendelsohn,Gordon B. Mills,Funda Meric-Bernstam,George R. Simon +13 more
TL;DR: This review outlines the recent developments in the understanding and treatment of tumors with ALK alterations and proposes targeting strategies to counteract the newly emergent mechanism(s) of ALK inhibitor resistance.
Related Papers (5)
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
Alice T. Shaw,Dong Wan Kim,Kazuhiko Nakagawa,Takashi Seto,Lucio Crinò,Myung-Ju Ahn,Tommaso De Pas,Benjamin Besse,Benjamin Solomon,Fiona H Blackhall,Yi-Long Wu,Michael Thomas,Kenneth J. O'Byrne,Denis Moro-Sibilot,D. Ross Camidge,Tony Mok,Vera Hirsh,Gregory J. Riely,Shrividya Iyer,V. Tassell,Anna Polli,Keith D. Wilner,Pasi A. Jänne +22 more
Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer
Alice T. Shaw,Dong Wan Kim,Ranee Mehra,Daniel Shao-Weng Tan,Enriqueta Felip,Laura Q.M. Chow,D. Ross Camidge,Johan Vansteenkiste,Sunil Sharma,Tommaso De Pas,Gregory J. Riely,Benjamin Solomon,Juergen Wolf,Michael Thomas,Martin Schuler,Martin Schuler,Geoffrey Liu,Armando Santoro,Yvonne Y. Lau,Meredith Goldwasser,Anthony Boral,Jeffrey A. Engelman +21 more
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Eunice L. Kwak,Yung-Jue Bang,D. Ross Camidge,Alice T. Shaw,Benjamin Solomon,Robert G. Maki,Sai-Hong Ignatius Ou,Bruce J. Dezube,Pasi A. Jänne,Daniel B. Costa,Marileila Varella-Garcia,Woo-Ho Kim,Thomas J. Lynch,Panos Fidias,Hannah Stubbs,Jeffrey A. Engelman,Lecia V. Sequist,Weiwei Tan,Leena Gandhi,Mari Mino-Kenudson,Greg C. Wei,S. Martin Shreeve,Mark J. Ratain,Jeffrey Settleman,James G. Christensen,Daniel A. Haber,Keith D. Wilner,Ravi Salgia,Geoffrey I. Shapiro,Jeffrey W. Clark,A. John Iafrate +30 more
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.
D. Ross Camidge,Yung-Jue Bang,Eunice L. Kwak,A. John Iafrate,Marileila Varella-Garcia,Stephen B. Fox,Gregory J. Riely,Benjamin Solomon,Sai-Hong Ignatius Ou,Dong Wan Kim,Ravi Salgia,Panagiotis Fidias,Jeffrey A. Engelman,Leena Gandhi,Pasi A. Jänne,Daniel B. Costa,Geoffrey I. Shapiro,Patricia LoRusso,Katherine Ruffner,Patricia Stephenson,Yiyun Tang,Keith D. Wilner,Jeffrey W. Clark,Alice T. Shaw +23 more